Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device.
Action Potentials
Aged
Atrial Appendage
/ physiopathology
Atrial Fibrillation
/ diagnosis
Atrial Function, Left
Cardiac Surgical Procedures
/ adverse effects
Female
Fibrinolytic Agents
/ administration & dosage
Heart Rate
Hemorrhage
/ mortality
Humans
Incidence
Ligation
Male
Middle Aged
Poland
Prospective Studies
Registries
Risk Assessment
Risk Factors
Stroke
/ mortality
Thromboembolism
/ mortality
Time Factors
Treatment Outcome
United States
atrial fibrillation
epicardial
left atrial appendage
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
02
05
2019
revised:
05
09
2019
accepted:
06
10
2019
pubmed:
10
10
2019
medline:
21
10
2020
entrez:
10
10
2019
Statut:
ppublish
Résumé
Left atrial appendage closure (LAAC) with LARIAT has emerged as one of the alternatives to oral anticoagulation (OAC) in patients with nonvalvular atrial fibrillation (AF). Our aim was to study long-term outcomes in patients undergoing LARIAT procedure. We analyzed patients screened for LARIAT device in four centers between December 2009 and June 2012. Out of these, patients who didn't undergo LAAC with the LARIAT device due to unfavorable LAA morphology and other preprocedural contraindications were included in control group. We analyzed thromboembolism, bleeding events, and mortality between LAA and control group. About 153 patients were screened. Out of these, 108 (70.6%) patients underwent LARIAT placement (LAA arm) and 45 (29.4%) excluded patients were included in control arm. There were no differences in CHADS Long-term data from routine clinical practice from our study suggests that LAA exclusion with LARIAT device is an effective treatment in management of nonvalvular AF patients with high risk of stroke, bleeding, and mortality. Further randomized trials, such as aMAZE, will provide more insight in this expanding field.
Sections du résumé
BACKGROUND
Left atrial appendage closure (LAAC) with LARIAT has emerged as one of the alternatives to oral anticoagulation (OAC) in patients with nonvalvular atrial fibrillation (AF). Our aim was to study long-term outcomes in patients undergoing LARIAT procedure.
METHODS
We analyzed patients screened for LARIAT device in four centers between December 2009 and June 2012. Out of these, patients who didn't undergo LAAC with the LARIAT device due to unfavorable LAA morphology and other preprocedural contraindications were included in control group. We analyzed thromboembolism, bleeding events, and mortality between LAA and control group.
RESULTS
About 153 patients were screened. Out of these, 108 (70.6%) patients underwent LARIAT placement (LAA arm) and 45 (29.4%) excluded patients were included in control arm. There were no differences in CHADS
CONCLUSIONS
Long-term data from routine clinical practice from our study suggests that LAA exclusion with LARIAT device is an effective treatment in management of nonvalvular AF patients with high risk of stroke, bleeding, and mortality. Further randomized trials, such as aMAZE, will provide more insight in this expanding field.
Substances chimiques
Fibrinolytic Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2849-2857Subventions
Organisme : National Polish Science Centre
ID : UMO 2014/13/D/NZ5/01351
Pays : International
Organisme : National Polish Science Centre
ID : UMO 2015/17/B/NZ5/00125
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm. 2011;8:188-193.
Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:108-118.
Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardio-thoracic Surg. 2000;17:718-722.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370-2375.
Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-953.
Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759.
Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(33):2719-2747.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(130):2071-2104.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists (8th Edition). Chest. 2008;133:160S-198S.
Han FT, Bartus K, Lakkireddy D, et al. The effects of LAA ligation on LAA electrical activity. Heart Rhythm. 2014;11:864-870.
Betts TR, Leo M, Panikker S, et al. Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: a multicenter registry. Catheter Cardiovasc Interv. 2017;89:484-492.
Lakkireddy D, Afzal MR, Lee RJ, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm. 2016;13:1030-1036.
Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure. J Am Coll Cardiol. 2017;70:2964-2975.
Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy. JACC: Cardiovasc Interv. 2009;2:594-600.
Wiebe J, Franke J, Lehn K, et al. Percutaneous left atrial appendage closure with the watchman device. JACC: Cardiovasc Interv. 2015;8:1915-1921.
Seeger J, Bothner C, Dahme T, et al. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. Clin Res Cardiol. 2016;105:225-229.
Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm. 2015;12(7):1501-1507.
Nakai T, Lesh MD, Gerstenfeld EP, Virmani R, Jones R, Lee RJ. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation. 2002;105:2217-2222.
Bartus K, Morelli RL, Szczepanski W, Kapelak B, Sadowski J, Lee RJ. Anatomic analysis of the left atrial appendage after closure with the LARIAT device. Circ: Arrhythmia Electrophysiol. 2014;7:764-767.
Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2551-2556.
Chatterjee S, Herrmann HC, Wilensky RL, et al. Safety and procedural success of left atrial appendage exclusion with the Lariat device: a systematic review of published reports and analytic review of the FDA MAUDE database. JAMA Intern Med. 2015;175:1104-1109.
Turagam Mohit K, Koerber S, Vuddanda V, et al. Abstract 21017: a systematic review and meta-analysis on success and complications of epicardial access. Circulation. 2017;136:A21017-A21017.
Jazayeri MA, Vuddanda V, Parikh V, Lakkireddy DR. Percutaneous left atrial appendage closure: current state of the art. Curr Opin Cardiol. 2017;32:27-38.
Maybrook R, Pillarisetti J, Yarlagadda V, et al. Electrolyte and hemodynamic changes following percutaneous left atrial appendage ligation with the LARIAT device. J Interv Card Electrophysiol. 2015;43:245-251.
Atoui M, Pillarisetti J, Iskandar S, Earnest M, Lakkireddy D. Left atrial appendage tachycardia termination with a LARIAT suture ligation. J Atr Fibrillation. 2015;8:1380.
Badhwar N, Mittal S, Rasekh A, et al. Conversion of persistent atrial fibrillation to sinus rhythm after LAA ligation with the LARIAT device. Int J Cardiol. 2016;225:120-122.